Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 966-974

  Van Rhee, Frits ^a   Wong, Raymond S ^b   Munshi, Nikhil ^c   Rossi, Jean Francois ^d   Ke, Xiao Yan ^e   Fosså, Alexander ^f   Simpson, David ^g   Capra, Marcelo ^h   Liu, Ting ⁱ   Hsieh, Ruey Kuen ^j   Goh, Yeow Tee ^k   Zhu, Jun ^l   Cho, Seok Goo ^m   Ren, Hanyun ⁿ   Cavet, James ^o   Bandekar, Rajesh ^p   Rothman, Margaret ^p   Puchalski, Thomas A ^p   Reddy, Manjula ^p   van de Velde, Helgi ^p   Vermeulen, Jessica ^q   Casper, Corey ^r   more..

^a Myeloma Institute for Research and Therapy   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HÔPITAL SAINT ELOI   (France)

^e PEKING UNIVERSITY THIRD HOSPITAL   (China)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g NORTH SHORE HOSPITAL   (New Zealand)

^h HOSPITAL MÃE DE DEUS   (Brazil)

ⁱ SICHUAN UNIVERSITY   (China)

^j MACKAY MEMORIAL HOSPITAL   (Taiwan)

^k SINGAPORE GENERAL HOSPITAL   (Singapore)

^l PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^m The Catholic University of Korea   (South Korea)

ⁿ PEKING UNIVERSITY FIRST HOSPITAL   (China)

^o CHRISTIE HOSPITAL   (United Kingdom)

^p JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^q Janssen Research and Development   (Netherlands)

^r Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERFERON; PLACEBO; PREDNISONE; RITUXIMAB; SILTUXIMAB; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; LOWER RESPIRATORY TRACT INFECTION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CANCER; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW UP; GIANT LYMPH NODE HYPERPLASIA; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INFUSIONS, INTRAVENOUS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84905005470     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70319-5     Document Type: Article

References (26)

1. Castleman B, Towne VW Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C Cabot. N Engl J Med 1954, 251:396-400.
2. Castleman B, Iverson L, Menendez VP Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956, 9:822-830.
3. Gaba AR, Stein RS, Sweet DL, Variakojis D Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978, 69:86-90.
4. Talat N, Belgaumkar AP, Schulte KM Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg 2012, 255:677-684.
5. Casper C The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005, 129:3-17.
6. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012, 87:997-1002.
7. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010, 8:486-498.
8. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106:2627-2632.
9. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013, 19:3659-3670.
10. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010, 28:3701-3708.
11. Cronin DM, Warnke RA Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009, 16:236-246.
12. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
13. Trikha M, Corringham R, Klein B, Rossi JF Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
14. Mehra M, Cossrow N, Stellhorn RA, Vermeulen J, Desai A, Munshi NC Use of a claims database to characterize and estimate the incidence of Castleman's disease. Blood 2012, 120. abstract 4253.
15. Robinson D, Reynolds M, Casper C, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol 2014, 165:39-48.
16. FDA approves Sylvant for rare Castleman's disease US Food and Drug Administration, (accessed April 29, 2014). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm.
17. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) March 17-20, 2014 (accessed April 28, 2014). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002044.jsp&mid=WC0b01ac058004d5c1.
18. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2013, 122:4189-4198.
19. Casper C, Voorhees PM, Fayad LE, et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman's disease. Blood 2013, 122:1806.
20. Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006, 76:119-123.
21. Ide M, Ogawa E, Kasagi K, Kawachi Y, Ogino T Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab. Br J Haematol 2003, 121:818-819.
22. Bower M How I treat HIV-associated multicentric Castleman disease. Blood 2010, 116:4415-4421.
23. Marietta M, Pozzi S, Luppi M, et al. Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report. Eur J Haematol 2003, 70:181-182.
24. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005, 78:302-305.
25. Talat N, Schulte KM Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 2011, 16:1316-1324.
26. Fajgenbaum DC, van Rhee F, Nabel CS HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014, published online May 8. 10.1182/blood-2013-12-545087.